Clinical Trial Update: Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant dose-dense gemcitabine and cisplatin trial in muscle-invasive bladder cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-02